[[Image:Acne market.jpg|center]]
{|border="0" cellspacing="0" cellpadding = "0" width="100%"
|align = "center"|<font color="#282828"><font size = "4">'''THE ACNE PRODUCT PIPELINE'''</font>
|-
|align = "center"|
|-
|}
{|border="2" cellspacing="0" cellpadding="4" width="100%" align="center"
|align = "center"|</font><br>''' ''' '''Product'''
|align = "center"|''' '''<br>'''Company'''
|align = "center"|<br>''' Indication'''
|align = "center"|<br>'''Development Status'''
|-
|ACAT Inhibitor
|Graceway Pharmaceuticals
|Acne
|Phase II
|-
|ANT-1207 (botulinum toxin A)
|Anterios
|Acne vulgaris
|Phase II
|-
|ASC-J9
|AndroScience
|Acne vulgaris
|Phase II
|-
|AUS-131/doxycycline
|Nexgen Dermatologics
|Acne vulgaris
|Phase I/II
|-
|BLI-1100
|Braintree Laboratories
|Acne vulgaris
|Phase II
|-
|CD-07223
|Galderma R &D
|Acne
|Phase II
|-
|CD-2475-101
|Galderma Laboratories
|Acne vulgaris
|Phase I
|-
|Clindamycin/tretinoin topical combination
|Skinvisible Pharmaceuticals
|Acne
|In clinical trials
|-
|COL-177
|Onset Dermatologics
|Acne vulgaris
|In clinical trials
|-
|Duac Topical Gel low-dose clindamycin/benzoyl peroxide gel
|Stiefel, a GSK company
|Acne vulgaris
|Application submitted
|-
|E-0301
|Elorac
|Acne
|Phase III
|-
|IDP 107
|Valeant Pharmaceuticals
|Acne vulgaris
|Phase II
|-
|Isotretinoin
|Cipher Pharmaceuticals
|Acne
|Phase III
|-
|JNJ-10229570
|Johnson & Johnson
|Acne vulgaris
|Phase II
|-
|Metvixia
|PhotoCure methyl aminolevulinate
|Acne
|Phase II
|-
|NB-003 (nanoemulsion)
|NanoBio
|Acne
|Phase I
|-
|NVC-422
|Galderma
|Acne
|Phase I completed
|-
|Tazarotene foam (retinoid foam)
|Stiefel, a GSK company
|Acne vulgaris
|Phase III
|-
|Tretinoin topical
|Phosphagenics
|Acne
|Phase I
|-
|WC-3018
|Warner Chilcott
|Acne
|Phase II
|-
|WC-3035
|Warner Chilcott
|Acne
|Phase I
|-
|}<br clear="all">
{|border="0" cellspacing="0" cellpadding = "0" width="100%"
|<font color="#282828"> Source: Medicines in Development for Skin Diseases 2011, Pharmaceutical Research and Manufacturers of America</font>
|-
|}
== '''USA market study''' ==